The effects of gp120-mediated signal transduction in viral replication and immune dysfunction that leads to HIV pathogenesis is the major focus of this project. In the past we demonstrated the capacity of gp120 to engage the gut homing receptor, integrin alpha4beta7. The gut is the principal site of viral replication and CD4+ T cell depletion during the acute stage of infection. Based on this notion, we explored the role of alpha4beta7 expressing CD4+ T cells in HIV transmission. We tested this hypothesis in a NHP model of HIV/SIV infection, and determined that an antibody specific for alpha4beta7 prevented transmission in a rhesus macaque model of mucosal transmission. We subsequently tested the impact of this alpha4beta7 antagonist in an in vivo NHP study in the context of anti-retroviral (ART) treatment. SIV-infected monkeys were treated with ART initiated at 5 weeks post infection followed by infusions of the primatized antibody alpha4beta7 integrin administered every 3 weeks until week 32. These animals subsequently maintained low to undetectable viral loads and normal CD4+ T cell counts in plasma and gastrointestinal tissues for more than 9 months, even after all treatment was withdrawn. This combination therapy allowed macaques to effectively control viremia and reconstitute their immune systems without the need for further therapy. Of note, we have employed in our NHP studies a primatized version of vedolizumab, an FDA approved drug employed for the treatment of inflammatory bowel diseases (IBDs). The combination of ART and vedolizumab is now being tested in a human clinical trial.

Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code
Sivro, Aida; Schuetz, Alexandra; Sheward, Daniel et al. (2018) Integrin ?4?7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes. Sci Transl Med 10:
Santangelo, P J; Cicala, C; Byrareddy, S N et al. (2018) Early treatment of SIV+ macaques with an ?4?7 mAb alters virus distribution and preserves CD4+ T cells in later stages of infection. Mucosal Immunol 11:932-946
Calenda, Giulia; Keawvichit, Rassamon; Arrode-Brusés, Géraldine et al. (2018) Integrin ?4?7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques. J Immunol 200:810-820
Nawaz, Fatima; Goes, Livia R; Ray, Jocelyn C et al. (2018) MAdCAM costimulation through Integrin-?4?7 promotes HIV replication. Mucosal Immunol 11:1342-1351
Yolitz, Jason; Schwing, Catherine; Chang, Julia et al. (2018) Signal peptide of HIV envelope protein impacts glycosylation and antigenicity of gp120. Proc Natl Acad Sci U S A 115:2443-2448
Arthos, James; Cicala, Claudia; Nawaz, Fatima et al. (2018) The Role of Integrin ?4?7 in HIV Pathogenesis and Treatment. Curr HIV/AIDS Rep 15:127-135
Kijak, Gustavo H; Sanders-Buell, Eric; Chenine, Agnes-Laurence et al. (2017) Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathog 13:e1006510
Kijak, Gustavo H; Sanders-Buell, Eric; Chenine, Agnes-Laurence et al. (2017) Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathog 13:e1006620
Girard, Alexandre; Jelicic, Katija; Van Ryk, Don et al. (2017) Neutralizing and Targeting Properties of a New Set of ?4?7-Specific Antibodies Are Influenced by Their Isotype. J Acquir Immune Defic Syndr 75:118-127
Cicala, Claudia; Nawaz, Fatima; Jelicic, Katija et al. (2016) HIV-1 gp120: A Target for Therapeutics and Vaccine Design. Curr Drug Targets 17:122-35

Showing the most recent 10 out of 25 publications